MET and breast carcinoma: The recently demonstrated involvement of the GD2/c-Met axis in estrogen receptor (ER)-negative breast-cancer aggressiveness strongly supports anti-GD2 immunotherapeutic approaches for treatment of breast cancer, especially in subgroups of breast cancer subjects clustering on very aggressive breast cancer subtypes, such as triple-negative and metaplastic variants [28–30].